Neurocrine Biosciences, Inc. (NBIX) Q4 2007 Earnings Results

Neurocrine Biosciences Misses on EPS — Stock Down 6.1%

Neurocrine Biosciences reported a significant loss in EPS, which contributed to a 6.1% drop in stock price. The lack of revenue figures and guidance adds uncertainty for investors. The management's defensive tone indicates they are aware of the challenges ahead but remain focused on long-term objectives.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-3.35	N/A	-299.28%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management's tone was defensive, reflecting the difficulties encountered. They reiterated their focus on future growth strategies.

Management acknowledged the challenges faced during the quarter.

They emphasized a commitment to long-term goals despite current setbacks.

Neurocrine Biosciences Misses on EPS — Stock Down 6.1%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Misses on EPS — Stock Down 6.1%

Key numbers

Management commentary